vTv Therapeutics Appoints Rudy Howard as Chief Financial Officer

HIGH POINT, N.C.--(BUSINESS WIRE)--vTv Therapeutics LLC (vTv), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today announced the appointment of Rudy C. Howard as Chief Financial Officer.

"We are pleased to welcome an executive with Rudy Howard's extensive financial management experience"
Mr. Howard joins the Company with over 30 years of senior management experience, most recently serving as CFO at SciQuest, an international spend management software company. Previously, he served as Senior Vice President and CFO at MDS Pharma Services, a multi-national pharmaceutical services organization. Before joining MDS, Mr. Howard served as CFO at several companies including PPD, Inc., a global pharmaceutical organization. Earlier in his career, he was a partner with PricewaterhouseCoopers.

"We are pleased to welcome an executive with Rudy Howard's extensive financial management experience," said Steve Holcombe, President and CEO of vTv Therapeutics. "We look forward to his contributions in this next stage of the Company's growth as we advance our pipeline of Alzheimer's and Type 2 diabetes drug candidates."

Mr. Howard received his B.A. in Accounting from North Carolina State University and is a Certified Public Accountant.

About vTv Therapeutics LLC

vTv Therapeutics LLC is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer's disease and type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

Contacts

Investors
The Trout Group
Marc Panoff, 646-378-2958
[email protected]
or
Media
BMC Communications
Brad Miles, 646-513-3125
[email protected]

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.